SEC Form 3 · accession 0001493152-26-043796
Nasus Pharma Ltd · NSRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Oren Elmaliah
Officer — Interim CFO
Period of report
Sep 19, 2026
Accepted (ET)
Sep 23, 2026 · 6:14 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0002029039
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share options (right to buy)F1 | $1.2264 | holding | — | — | — | Jun 13, 2020 | Nov 28, 2029 | Ordinary Shares | 24,680 | — | D |
| Share options (right to buy)F2 | $6.0462 | holding | — | — | — | Jan 17, 2025 | Jan 17, 2035 | Ordinary Shares | 27,460 | — | D |
Explanation of responses
- F1Options to purchase 24,680 ordinary shares of the Issuer, no par value ("Ordinary Shares") were granted on November 28, 2019. As of September 18, 2026, 24,680 options remain outstanding, all of which are vested and exercisable, at an exercise price of $1.2264 per share, expiring November 28, 2029.
- F2Options to purchase 27,460 Ordinary Shares were granted on January 17, 2025, with the total grant vesting in equal quarterly installments of 8.33% commencing on January 17, 2025. As of September 18, 2026, 13,840 are vested and exercisable, at an exercise price of $6.0462 per share, expiring January 17, 2035.